View all stories with this category.
Derek Lowe makes the case against using ‘frequent hitters’ in your assays
Derek Lowe would back a team of risk takers if he had to
Chemists and biologists often view the process of drug discovery very differently
It took Derek Lowe a while to find his motivation
How long is ‘too long’ in the drug discovery game?
Drug discovery requires experimentation, says Derek Lowe. But chemists can be reluctant to stray from the elements they know and love
Derek Lowe wonders what the lab lingua franca might be in the years to come
Derek Lowe discusses how companies are increasingly trying to do more with the compounds they already know a lot about
Derek Lowes considers the perfect lab environment
Derek Lowe discusses the compounds you can buy but won't see anywhere in the literature
You have to make space for good sense when thinking about safety, argues Derek Lowe
Derek Lowe considers an increasingly popular business strategy in the drug industry, the much discussed 'pay for delay' deal
Derek Lowe highlights the less visible pitfalls on the road to a new drug
The financial markets can be a rollercoaster ride, writes Derek Lowe, so should chemists working in industry worry about the company share price?
To the unfamiliar, chemists might all look the same. But some common categories are easy to identify, explains Derek Lowe
The map of scientific disciplines is growing ever more complex. Derek Lowe surveys the country
'Natural products are back!' is a headline Derek Lowe has seen several times before
Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations
Enzymes have been giving chemists inferiority complexes since day one, says Derek Lowe. But there's no denying their potential
Some medicinal chemists can't get enough fluorines in their molecules. Derek Lowe explains the love-hate relationship
© Royal Society of Chemistry Registered charity number: 207890
Site powered by Webvision Cloud